Canopy Growth Corporation

NASDAQ:CGC

Drug Manufacturers - Specialty & Generic

Healthcare
$0.50 +1.07%

+$0.01 today

Market cap
$212.31M
Beta
0.78
P/E (TTM)
-1.8
EPS (TTM)
-$0.76
52W Low $0.84High $2.38

Volume 3.44M

Average 9.97M

CGC Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Canopy Growth CorporationNASDAQ: CGC

Selling, General & Admin · Q4 FY2025 · quarter ended Mar 2026

Selling, general & admin growth accelerates

Q4 FY2025 selling, general & admin of CA$31.17M rose 253.7% year over year, ahead of the +10.1% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 23.7% from the prior quarter. Over 3 fiscal years it compounded at -9.2% a year.

Context

  • Selling, general & admin amounted to 46.1% of revenue in FY2025, up 0.9 pp from a year earlier.
  • Selling, general & admin increased in 1 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of CA$147.72M (-33.8%) for the fiscal year ending Mar 2027, a slowdown from the +83.3% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$31.17M-23.7% QoQ
Last fiscal yearMar 2026
CA$223.11M+83.3% YoY
LTMMar 2026
CA$134.01M+10.1% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+253.7%+20.3%-233.4 pp
1 year+83.3%-33.8%-117.1 pp
3-year CAGR-9.2%-8.9%+0.3 pp
5-year CAGR-3.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

CAD · from the income statement

Latest · FY2025
223.11M CAD
Year-over-year change
+83.3%
4-year CAGR
-11.3%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How CGC compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +10.1% is the 2nd highest of 9, against a peer median of -0.7%.
  • Selling, general & admin amounts to 42.9% of revenue for CGC, versus a peer median of 60.1%.
CGC Competitors
Selling, General & Admin for CGC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026CA$166.84M CAD+0.2%+0.7%53.7%
CGCCanopy Growth CorporationLTM Mar 2026CA$134.01M CAD+10.1%-9.2%42.9%
DHDefinitive Healthcare Corp.LTM Mar 2026$132M USD+3.7%-1.9%55.4%
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$70.03M USD-34.3%-10.8%19.4%
LYELLyell Immunopharma, Inc.LTM Mar 2026$40.64M USD-22.7%-27.3%131109.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$33.33M USD—+8.3%24.7%
BIOABioAge Labs, Inc.LTM Mar 2026$28.7M USD+27.8%+43.3%278.2%
CABACabaletta Bio, Inc.LTM Mar 2026$28.39M USD-5.3%+25.8%—
TKNOAlpha Teknova, Inc.LTM Mar 2026$27.13M USD-1.6%-10.3%64.9%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$22.58M USD+5.5%-4.4%269.8%
Peer median (excluding CGC) —-0.7%-1.9%60.1%

Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Mar 2022
FY2022
Mar 2023
FY2023
Mar 2024
FY2024
Mar 2025
FY2025
Mar 2026
Revenue475.7M333.25M297.15M269M483.67M
Cost of Revenue663.11M396.78M216.26M189.48M386.51M
Gross Profit(187.41M)(63.53M)80.88M79.51M97.16M
Gross Margin-39.4%-19.1%27.2%29.6%20.1%
Research & Development32.26M21.72M4.61M1.91M0
Selling, General & Admin361.1M297.98M180.59M121.71M223.11M
Operating Expenses831.39M2.57B309.6M196.65M322.6M
Depreciation & Amortization110.94M80.03M53.18M43.12M50.86M
EBITDA(52.98M)(2.88B)(312.83M)(479.31M)50.86M
EBITDA Margin-11.1%-864.2%-105.3%-178.2%10.5%
Operating Income(1.02B)(2.63B)(228.71M)(117.14M)(161.66M)
Operating Margin-214.2%-789.3%-77.0%-43.5%-33.4%
Interest Income6.6M24.28M16.24M8.82M10M
Interest Expense103.94M126.16M105.35M74.57M38.19M
Other Income / Expenses750.94M(455.64M)(242.64M)(479.85M)(101.23M)
Income Before Tax(267.86M)(3.09B)(471.36M)(597M)(262.89M)
Pre-Tax Margin-56.3%-926.1%-158.6%-221.9%-54.4%
Income Tax Expense(8.95M)(5.73M)12.33M7.14M23K
Net Income(310.04M)(3.28B)(657.27M)(598.12M)(366.64M)
Net Margin-65.2%-983.7%-221.2%-222.4%-75.8%
EPS (Basic)(7.70)(70.70)(6.47)(5.53)(0.88)
EPS (Diluted)(7.70)(70.70)(8.79)(5.53)(0.88)
Weighted Avg Shares39.13M46.37M101.63M107.55M2.98B
Weighted Avg Shares (Diluted)39.13M46.37M74.79M107.55M2.98B

Canopy Growth Corporation

NASDAQ:CGC

Intrinsic Alpha fair value

Locked

Current Price

$0.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.